Oliver W. Press

Medicine · Health Sciences

84h-index27.2kcitations585works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(314), Radiopharmaceutical Chemistry and Applications(174), Monoclonal and Polyclonal Antibodies Research(165), Chronic Lymphocytic Leukemia Research(79), CAR-T cell therapy research(68)

Publications585 total

NA
immuneACCESS·2024
Data from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
2023Open Access
Supplementary Materials and Methods from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTA
2023Open Access
Data from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTA
2023Open Access
Data from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTA
2023Open Access
Supplementary Figures 1 through 10 from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
2023Open Access
Data from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
2023Open Access
Supplementary Figures 1 through 10 from Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab
2023Open Access
Supplementary Materials and Methods from Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTA
2023Open Access
Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
2023Open Access
Supplementary Figure 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
2023Open Access
Supplemental Figures 1 through 5 from Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
2023Open Access
Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
2023Open Access
Data from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
2023Open Access
Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
2023Open Access
Supplementary Table 2 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
2023Open Access
Data from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
2023Open Access
Supplementary Table 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
2023Open Access
Data from Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
2023· 1 citedOpen Access
Data from Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas
2023Open Access
page 1 of 30Next →

Frequent Co-authors

Frederick R. Appelbaum(12), David G. Maloney(12), Janet F. Eary(11), Dana C. Matthews(11), Irwin D. Bernstein(11), Ajay K. Gopal(9), Paul J. Martin(9), Darrell R. Fisher(8), Richard I. Fisher(7), Andrew D. Zelenetz(6), Julie M. Vose(6), Brian G. Till(5), Michael C. Jensen(5), Jinjuan Wang(5), Ranjana H. Advani(5), Michael LeBlanc(5), Laurie H. Sehn(5), Bruce D. Cheson(5), Lawrence D. Durack(5), Ted Gooley(5)